Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Seaweed yields new compounds with pharmaceutical potential

14.10.2005


Researchers have discovered 10 new molecular structures with pharmaceutical potential in a species of red seaweed that lives in the shallow coral reef along the coastline of Fiji in the south Pacific Ocean.



Some of these natural compounds showed the potential to kill cancer cells, bacteria and the HIV virus, according to research at the Georgia Institute of Technology. In fact, two of them exhibit anti-bacterial activity towards antibiotic-resistant Staphylococcus aureus at concentrations worth pursuing, though researchers don’t know yet whether the concentrations of the compounds required to kill the bacterium would be harmful to humans.

The compound that was isolated in the greatest abundance -- named bromophycolide A by the researchers -- killed human tumor cells by inducing programmed cell death (called apoptosis), a mechanism that is promising for development of new anti-cancer drugs, researchers noted.


The findings on three of these compounds – called diterpene-benzoate natural products -- are reported in the Oct. 12 online issue of the American Chemical Society journal Organic Letters. Information on the other compounds will be published later. The research, which is part of an environmental conservation, economic development and drug discovery project in Fiji, was primarily funded by the Fogarty International Center at the National Institutes of Health. Georgia Tech Professor of Biology Mark Hay leads the project, which also aims to benefit the Fijian government and villages, which own their local natural resources and will benefit monetarily if these natural resources become marketable drugs.

"We’re only at the test-tube level so far," explained Julia Kubanek, a Georgia Tech assistant professor of biology, chemistry and biochemistry, who is the lead author on the paper. "The next step is to discover how these compounds work and then to study them in a more complex model system."

The U.S. pharmaceutical company Bristol Myers Squibb is collaborating with Georgia Tech researchers to determine how some of these 10 compounds kill cancer cells. Meanwhile, Georgia Tech has filed a provisional patent to protect the discovery of these structures and small variations of them.

"These molecular structures are curious in the way carbon atoms are attached," Kubanek said. "It’s very unusual. They represent a new category of organic molecules. It’s exciting as a biochemist to observe that living organisms have evolved the ability to synthesize such unique and exotic structures compared to other molecules typically produced by seaweeds."

The source of these new molecular structures is a red seaweed (Callophycus serratus) collected from four Fijian sites. Among the sites, researchers found variations in the molecular structures produced by the species.

"There are chemical differences among populations of this seaweed species, even though two of the sites where it was collected are only about 2 kilometers apart," Kubanek noted. "… This shows us there are small, but valuable differences within species, and this genetic biodiversity is important to protect as a resource for the future." Researchers have been analyzing extracts from about 200 marine plant and invertebrate animal samples they collected from the Fijian coral reef in June 2004 with the permission of the Fijian government and local resource owners.

"Marine organisms make molecules for their own purposes that we might co-opt for our own use as pharmaceutical agents," Kubanek explained. "The organisms’ purposes include defense against predators, the ability to fight diseases, and the production of chemical cues, such as those used for sex recognition."

Hay, Kubanek, and their colleagues collected baseball-sized samples of reef species that exhibit unusual growth and/or behavioral phenomena. Among their collection were soft corals, marine sponges, slugs, and green, red and brown seaweeds.

In the lab, researchers extracted these organisms using mixtures of organic liquids, which opened up the cells and dissolved the natural products. The organic liquids were then removed from the extract by evaporation, and small quantities of each extract were tested against a battery of pharmaceutical drug targets, including malarial parasite, tuberculosis-causing bacteria, and several cancers.

Typically, these tests involve exposing live, disease-causing cells -- parasites, bacteria or cancer cells -- to an extract and then assessing cell death compared to cells that were not exposed to extracts. Georgia Tech scientists then prioritized further study of extracts that had strong effects on these disease-causing cells.

The Callophycus red seaweed was one of the first five species that researchers investigated to identify the compounds within extracts that caused strong effects against disease-causing cells. Anne Prusak, a former Georgia Tech student and research technician, separated the new molecules from other components of the extract by a process called chromatography, which takes advantage of the different chemical characteristics of compounds.

Finally, researchers used X-ray crystallography (work done at Emory University in Atlanta), nuclear magnetic resonance spectroscopy and mass spectral analyses to determine how carbon, oxygen, bromine and hydrogen atoms connected to make up the molecular structures of the 10 new natural products.

Much research is left to do before any of these compounds are used to formulate a drug available on the market, Kubanek said. It typically takes at least a decade from the discovery of a compound to the marketing of a new drug. If that does happen in this case, Fijian villagers and the Fijian government would benefit financially from the discovery because of an agreement that is already in place, she added. Because of the long timeframe in getting a drug to market, the project in Fiji provides other immediate conservation and economic development benefits to villagers and the government.

Jane M. Sanders | EurekAlert!
Further information:
http://www.edi.gatech.edu

More articles from Life Sciences:

nachricht Symbiotic bacteria: from hitchhiker to beetle bodyguard
28.04.2017 | Johannes Gutenberg-Universität Mainz

nachricht Nose2Brain – Better Therapy for Multiple Sclerosis
28.04.2017 | Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik IGB

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>